Lebrikizumab for Atopic Dermatitis Results in Long-Term Improvements Over 152 Weeks; These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an asses

Media coverage

• Title	Lebrikizumab for Atopic Dermatitis Results in Long-Term Improvements Over 152 Weeks; These long-term results from the ADjoin trial show that long-term lebrikizumab therapy may improve sleep disturbances, pruritus, and skin symptoms, using POEM as an asses
  Media name/outlet	Consultant Live
  Country/Territory	United States
  Date	12/12/24
  Persons	Peter Lio